IP Library Granted Patent US 7,972,770
Granted Patent B2
US 7,972,770 · App. 12/063,968 · Granted Jul 5, 2011

Methods of detection of cancer using peptide profiles

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,972,770
App. No.
12/063,968
Granted
Jul 5, 2011
Kind
B2
Abstract

The disclosed methods address the identification and monitoring of cancer in a subject using serum peptide profiles. Such profiles allow the detection of the differential presence of certain serum peptide markers in comparison with controls. The profiles can be determined employing mass spectrometry.

Claims (24)

1. A method of generating a peptide profile of a subject having cancer of the prostate, comprising the steps of:

i) combining an exogenous peptide selected from the group consisting of a complement C3f, ITIH4, clusterin, complement C4-alpha, fibrinopeptide A, kininogen, factor XIII, fibrinogenA peptide and combinations thereof with a biological sample from the subject; and

ii) proteolytically digesting a peptide of step i), wherein combining the biological sample and said peptide proteolytically digests said peptide, and wherein the biological sample is serum or plasma,

thereby generating a peptide profile of the subject.

2. The method of claim 1 , wherein the exogenous peptide is labeled with an isotope.

3. The method of claim 1 , wherein the peptide profile indicates that the subject has cancer of the prostate.

4. A method of generating a peptide profile of a subject having cancer of the bladder, comprising the steps of:

i) combining an exogenous peptide selected from the group consisting of a complement C3f, ITIH4, clusterin, complement C4-alpha, fibrinopeptide A, bradykinin, APO A-I, APO A-IV, APO E, kininogen, fibrinogenA peptide and combinations thereof with a biological sample from the subject; and

ii) proteolytically digesting a peptide of step i), wherein combining the biological sample and said peptide proteolytically digests said peptide, and wherein the biological sample is serum or plasma,

thereby generating a peptide profile of the subject.

5. The method of claim 4 , wherein the exogenous peptide is labeled with an isotope.

6. The method of claim 4 , wherein the peptide profile indicates that the subject has cancer of the bladder.

7. A method of generating a peptide profile of a subject having cancer of the breast, comprising the steps of:

i) combining an exogenous peptide selected from the group consisting of a ITIH4, bradykinin, complement C4-alpha, fibrinopeptide A, complement C3f, APO A-IV, factor XIII, transthyretin, fibrinogenA peptide and combinations thereof with a biological sample from the subject; and

ii) proteolytically digesting a peptide of step i), wherein combining the biological sample and said peptide proteolytically digests said peptide, and wherein the biological sample is serum or plasma,

thereby generating a peptide profile of the subject.

8. The method of claim 7 , wherein the exogenous peptide is labeled with an isotope.

9. The method of claim 7 , wherein the peptide profile indicates that the subject has cancer of the breast.

10. A method of generating a peptide profile of a subject having cancer of the thyroid, comprising the steps of:

i) combining an exogenous peptide selected from the group consisting of a fibrinopeptide A, fibrinogenA peptide, complement C3f and combinations thereof with a biological sample from the subject; and

ii) proteolytically digesting a peptide of step i), wherein combining the biological sample and said peptide proteolytically digests said peptide, and wherein the biological sample is serum or plasma,

thereby generating a peptide profile of the subject.

11. The method of claim 10 , wherein the exogenous peptide is labeled with an isotope.

12. The method of claim 10 , wherein the peptide profile indicates that the subject has cancer of the thyroid.

Assignments (4)
CONFIRMATORY LICENSE Recorded Aug 31, 2023
From: SLOAN-KETTERING INST CAN RESEARCH
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 064767/0447 →
CONFIRMATORY LICENSE Recorded Jul 31, 2012
From: SLOAN-KETTERING INSTITUTE FOR CANCER RES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028687/0131 →
CONFIRMATORY LICENSE Recorded May 3, 2012
From: SLOAN-KETTERING INSTITUTE FOR CANCER RES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028147/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2008
From: TEMPST, PAUL; VILLANUEVA, JOSEP
To: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
Reel/Frame 021729/0761 →